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Vascular calcifications (VC) of the intima are primarily related to atherosclerosis and VC of the media 
are related to a host of disorders classically described by Mönckeberg in the arteries of the extremities, 
now termed Mönckeberg’s media sclerosis (MMS). MMS related VC represent frequent clinical 
findings in the elderly and in patients with type II diabetes and chronic renal disease. Based on current 
understanding, MMS related VC result from active biological processes causing precipitation and 
crystallization of ionic intra- and extra- cellular forms. In this article we review the current state of 
knowledge about the clinical pathology, molecular biology and diagnostics of MMS, expand on 
potential mechanisms responsible for poor prognosis in patients with MMS and expose some of the 






















Vascular calcifications (VC) are of similar composition to bone minerals. In Mönckeberg’s media 
sclerosis (MMS) VC are, in principal, deposits of hydroxyapatite with high degree of crystallization 
(1). Initially vascular calcifications were thought to be the result of passive degenerative processes, 
however, recent studies illustrate that vascular calcification is an active process initiated via a variety 
of molecular signaling pathways (2). While considerable progress elucidating the signaling pathways 
regulating VC formation has been achieved, the exact molecular basis of VC still remains elusive (3). 
 
With incoming new research data the already large number of molecular mechanisms suggested to 
contribute to VC formation continues to grow. It appears that while deposition of hydroxyapatite 
represents the ultimate common pathway of VC in MMS, different initiating and propagator molecular 
mechanisms as well as different crystalline composition of calcium apatite crystals may be present in 
other forms of VC (4). For example, it seems likely that vascular calcification processes associated 
with atheroma formation may be triggered by specific biochemical cascades that are altogether 
different from the cascades initiated by primary damage to elastic fibers; however both ultimately 
result in ectopic VC. While experimental conditions may replicate parts of the calcification process in 
a given model they may not provide the whole picture in even any of these specific conditions. Thus, 
some of the emerging molecular complexity of VC may be possibly accounted for by differences in 
experimental designs as well as disregard for specific etiologies of VC types. 
 
We believe that one of the obstacles to the progress of understanding molecular biology of VC can be 
found in the various differences in experimental designs and tendencies to unite a host of different 
findings associated with different types of VC under a single umbrella hypothesis. Misappropriation of 
MMS as a form of atherosclerosis spans more than 150 years of medical research and provides a 
textbook example of this glaring inaccuracy (see, Appendix A - Historical perspective). Furthermore, 
because of the paucity of stenotic changes most cases of MMS were, until recently, considered a 
secondary signature of numerous diseases as opposed to a distinct pathological process of its own. It 
was only in the early 1980’s that the first reports concerning the negative prognostic value of MMS in 
diabetics and patients with end-stage renal disease were published (5, 6). Nevertheless, the exact 
mechanisms responsible for poor prognosis of patients with MMS have not yet been fully clarified. To 
date physicians attribute the gradual stiffening of the large conduit vessels as the cause of poor clinical 




In this article we review the current state of knowledge about the clinical pathology, molecular biology 
and diagnostics of MMS, expand on potential mechanisms responsible for poor prognosis in patients 
with MMS and expose some of the directions for future research.  
 
Prevalence and incidence 
The prevalence of MMS in the general population is not known. Peripheral Atherosclerotic Occlusive 
Disease (PAOD) is classified as having an ankle-brachial index (ABI) of <0.9; the prevalence of 
PAOD ranges between 3-5% for persons 50 years old and 15-40% among persons 80 years old. 
Comparatively, the prevalence of MMS in the general population, based on ABI >1.3, has been 
estimated to be 0.5%; it is more prevalent in men compared to women (3:2) and the highest prevalence 
of MMS has been observed in type II diabetics ranging between 4-9% (8), depending on age and 
duration of diabetes (9). In patients with type II diabetes and chronic renal disease MMS has been also 
recognized as an independent risk factor for cardiovascular events (5-7, 9, 10). Less frequently MMS 
has been reported in association with a number of other diseases (see, Appendix B). MMS has also 
been reported in absence of other diseases or any other known risk factors (11), and is frequently 
associated with aging (12). 
 
Topography  
Originally, as described by Mönckeberg, MMS has been located in the muscular arteries of the lower 
and upper extremities (13). Subsequently, MMS lesions confirmed by histology were also observed in 
large elastic type arteries (ascending aorta), medium-sized visceral or kidney arteries, small arteries 
(coronary, temporal, uterine, ovarian, parathyroid, mammary gland and other) with diameter of at least 
0.5 mm (14-17). A systemic distribution of MMS appears uncommon (18), yet the true incidence 
remains unknown.  
 
Histopathology  
The VC seen in MMS is clearly distinct from the pathology of atherosclerosis, where VC is primarily 
localized in the intima. MMS lesions, whether in elastic, transitional or muscular type arteries, appear 
identical when examined microscopically. The four stages of lesions progression distinguish the extent 
and severity of MMS.. In stage 1, calcifications appear on haematoxylin-eosin, (H&E), staining as 
irregular blue or violet deposits embedded within the media. In the absence of atherosclerosis the 
intima shows subendothelial hyperplasia. On high resolution light microscopy (40 x – 1000 x 
magnification) using H&E, Elastica-van-Gieson, von Kossa or Alizarin staining deposits consisting of 
fine granulations, which increase in size and become confluent with time are revealed (Figure 1a). 
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Both intra- and extracellular deposits are present. Intracellular deposits are located in vascular smooth 
muscle cells (VSMC); extracellular deposits are largely associated with damaged and fractured elastic 
fibers embedded within the extracellular matrix (Figure 1b). In some cases, MMS lesions are also 
associated with the internal elastic membrane (19). In muscular and transitional arteries, on HE-
staining granular calcifications develop alongside the internal elastic membrane (Figure 1c). These 
bands of calcium-rich deposits may thicken becoming solid plates extending deep into the inner layer 
of the media. With further progression of the disease calcifications may distort the junctions of the 
innermost and outermost layers of the media spanning up to three quadrants of the cross-section (stage 
2, Figure 1d) or it may occur involving the entire circumference (stage 3, Figure 1e). In stages 2 and 3 
large conglomerates of calcifications may form solid plates and sheaths progressively distorting the 
architecture of the media; intrusions upon the intima are then common (20). In stage 4 of MMS foci of 
bone formation within the arterial media may be found, calcifications may undergo osseous metaplasia 
giving rise to true bony trabeculae. These structures delineate true medullary spaces harboring 
hematopoietic cells interspersed with adipocytes (21); Virchow, Mönckeberg, and other pathologists 
made these observations over the course of the 19
th
 and early 20
th
 century.  
 
In the arterial wall, calcification deposits associated with MMS may be perceived as foreign bodies 
and induce granuloma formation; these structures often contain multinucleated giant cells. Other 
inflammatory components such as foam cells, lymphocytes, and mast cells may be also present, yet in 
contrast to atherosclerosis they are absent in early stages and they do not represent the key findings. 
Large calcifications may induce subendothelial hyperplasia characterized by an increase of cellularity 
(e.g. myofibroblasts, fibroblasts, fibrocytes), ulcerate into the intima or even protrude into the lumen. 
These particular lesions may become niduses for thrombosis or they may detach and cause peripheral 
embolism (22). It should be noted that MMS lesions do not regress and the clinical complications may 
occur according to the site and the amount of calcification. In addition, presence of MMS is not 
necessarily indicative of an occlusive atherosclerotic peripheral artery disease, yet the co-incidence of 
both entities particularly in diabetics is common. Anatomically, MMS lesions also involve the 
microcirculation, e.g. arterioles (10 to 500 µm in diameter).  However, neither the extent of MMS 
lesions in the periphery of the arterial tree or the potential effects of MMS on microcirculation or 
endothelial function has been sufficiently studied. Calciphylaxis, presence of tissue necrosis involving 
mostly skin and skeletal muscle in patients with end-stage renal disease due to massive media 
calcifications of the large and small arteries including arterioles (23), may represent just a snippet of a 






Biochemistry and Molecular Biology  
Since the early description of ―endarteritis deformans‖ by Virchow, medial VC was considered a 
passive process of calcium phosphate deposition. However, twenty years ago, the pioneering work of 
Demer’s group (24) first described the expression of an osteoblast-reated gene (BMP2, a bone 
morphogenetic protein) in calcified human atherosclerotic lesions, a finding that was subsequently 
corroborated using additional osteogenes and calcification models (e.g. 25, 26) as well as in human 
MMS lesions. These discoveries initiated the view that VC is an active process of ossification, a 
pathogenic observation that was reinforced with the description of bone forming events, including the 
production of matrix vesicles and apoptotic bodies (27, 28). In parallel to this pathogenic view, results 
from several groups supported an alternate hypothesis that calcification is the consequence of the loss 
of local and/or circulating calcification inhibitors, such as matrix-Gla protein, (MGP), (29), 
pyrophosphate, fetuin A (30) and osteoprotegerin (31). Animal knockout studies further showed that 
loss of a single inhibitor could result in extensive medial calcification independent of atherosclerosis. 
While both pathogenic models are not mutually exclusive (32), a logical consequence of such 
dichotomy was the interpretation of the expression of bone-related genes as either the cause or the 
consequence of the calcification/deposition of calcium phosphate (e.g. 33). Clarification of this 
controversy is still pending, and is a question of major importance in the field of VC because therapies 
will differ depending on the true mechanism initiating the process of calcification. 
Over the last fifteen years, several proposals have tried to explain both, the active bone forming and 
the loss-of-inhibitor mechanisms of calcification, but so far none has been successful in explaining 
completely ectopic calcification (for excellent reviews that shows the evolution of theories see 32, 34, 
35). This is likely due to the complexity of the initiation events, signalling pathways and mechanisms 
that lead to VC particularly in MMS that forms over a long period of time. In addition, the use of 
different in vitro and in vivo laboratory models, cell culture conditions for growth and 
calcification/precipitation assays, animal strains and species, as well as experimental confusion 
between calcification versus mineral precipitation are among the controversies that slow the advance 
of knowledge on the pathological causes of the disease. The main consequence of this slow progress is 
the absence of efficacious treatments to prevent and treat this degenerative process.  
In recent years, intriguing experimentation from several groups using new VC disease models of 
chronic kidney disease (CKD)-related hyperphosphatemia is providing findings that strongly support 
some of the former hypothesise for the pathogenesis of VC. Patients with hyperphosphatemia induced 
by CKD develop rapid and extensive MMS, in part due to mineral dysregulation stemming from the 
primary renal disorder. Under these morbid conditions, vasculotoxicity of excess inorganic phosphate 
relies in part on the formation of nanocrystals with calcium and other ions, which nucleat and deposit 
in soft tissues, including the vascular wall (36). In the presence of physiological concentrations  of 
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inorganic phosphate (~1 mM Pi), calcification is only observed in specific genetic conditions that 
cause calcification (see below) and after long periods of exposure, either in vitro (33, 37, 38) or in vivo 
as in ageing (39, 40). However, in the presence of pathological hyperphosphatemic conditions calcium 
phosphate deposition is accelerated and easily observed. This strongly suggests that deposition is 
actively prevented by the presence and activity of calcification inhibitors, and that calcification is 
therefore accelerated when the limited capability of calcification inhibitors is overcome (33, 41). 
In contrast to bone, calcium phosphate in the arteries is not predominantly deposited on type I collagen 
but rather on the amorphous elastin that comprises the elastic lamellae (42). This process is accelerated 
when elastin is degraded by elastase and other proteases (43). Elastin is the main component of the 
connective tissue, which in combination with VSMCs, comprises the medial layer and spans the vessel 
wall circumference. While the elastin fibers can calcify both in vitro and in vivo as in elastocalcinosis 
(39, 43) the role of the VSMCs and accompanying cells is more complicated. There are at least three 
key aspects to be considered and elucidated in these cells regarding the pathogenesis of VC: i) the role 
of transformation into an osteochondrogenic phenotype, ii) the generation of nucleating structures for 
calcium phosphate deposition, and iii) the endocytosis and toxicity of calcium phosphate nanocrystals. 
On the one hand, the phenotypic plasticity of the mesenchymal VSMC leads them to trans-
differentiate in vitro into a ―synthetic‖ phenotype, as indicated above, with osteochondrogenic 
characteristics and the expression of bone-related transcription factors (Cbfa1/Runx2, Msx2), BMP2, 
alkaline phosphatase, osteopontin, etc., as evidenced in vitro and in vivo (e.g. 44, 45). The causes, 
consequences and identity of the specific cells that trans-differentiate still need to be elucidated (e.g. 
46). Multiple factors that activate these osteogenic pathways have been identified in vitro, however the 
pathways that dominate in vivo are not clearly defined. Recent findings that persistent DNA damage 
signalling that is associated with cellular senescence can activate osteogenic pathways in VSMCs is of 
significance, as ageing is the most dominant risk factor for the progression of media sclerosis (47, 48). 
In addition to these senescence associated osteogenic pathways, recent evidence strongly supports the 
view that osteogene expression is also a consequence of the nucleation of calcium phosphate crystals, 
as bone-related gene expression can be completely prevented with calcification inhibitors like 
pyrophosphate or phosphonoformic acid, even in the presence of high concentrations of calcium or 
phosphate (37, 38). In order to activate osteogenic gene expression, nanoparticles of 30-500 nm need 
to be endocytosed and accumulated in the lysosomes, where the crystals are then dissolved.  Increased 
calcium concentration in the cytosol can additionally be a cause of apoptosis and necrosis (37, 49). 
VSMCs also participate in the nucleation of calcium phosphate crystals through the formation of 
extracellular vesicles. Classification of these vesicles is a controversial area of research; recent 
attempts have been made to normalize nomenclature and classification (50). Matrix vesicles (30–300 
nm in diameter) and fragmented apoptotic bodies (50 to 5000 nm in diameter) are the most studied 
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vesicular structures in calcification (51). Matrix vesicles seem to be released by macrophages and 
VSMCs in calcified atheromas (52), but their role in medial calcification has been studied in less detail 
(53). Apoptotic bodies released by VSMCs can act as nucleating agents for the deposition of crystals 
in the aortic wall (27). As shown in vitro (28) and ex vivo (52) the production of apoptotic bodies and 
even matrix vesicles is dependent on the concentrations of calcium and phosphate, while normal 
vesicles contain inhibitors of calcification, especially in the presence of serum and do not initiate 
calcification (52, 53). Apoptosis of VSMCs is also associated with calcification and medial 
degeneration (54), and cell death can be caused by internalization of calcium phosphate crystals 
smaller than 1 µm and accumulation and dissolution in the lysosomes (49). Cell death is not restricted 
to apoptosis, and necrotic cell debris also has been shown to induce calcification in a mesenchymal in 
vitro model (54). 
Recently an additional cellular phenomenon has been described that counteract the pro-calcific effect 
of apoptosis: autophagy (55). In this process, proteins and organelles are engulfed into membrane 
vesicles named autophagosomes, which are delivered to lysosomes and degraded and recycled. It is an 
important mechanism to increase cell survival during stress and nutrient deprivation. Dai and 
collaborators found that blockade of autophagy increases calcification in response to very high 
phosphate concentrations, even in the presence of apoptosis inhibitors, while activating autophagy 
decreases calcification and the release of matrix vesicles. Recent findings suggest that the initiating 
events and the early pathogenic steps in the various ectopic calcification disorders may be different. 
Calcifying atherosclerosis, for example, occurs in the absence of hyperphosphataemia, and the strong 
inflammatory component is sufficient to create the conditions for nucleating calcium phosphates (56). 
The macrophage infiltrating response during atheroma formation is accompanied by the release of 
several pro-calcifying cytokines, which favours the osteogenic trans-differentiation of VSMC and/or 
increases apoptosis of VSMC, macrophages, etc. Matrix vesicles and apoptotic bodies then serve as 
nucleating sites for the deposition of calcium phosphate crystals. This localized inflammatory response 
has not been observed in MMS, in particular the macrophage accumulation in areas of medial 
calcification. During chronic kidney disease (a major cause of MMS), a generalized, non-localized 
pro-inflammatory status is observed, with overexpression of TNFα, which could activate the 
osteochondrogenic programme in VSMCs.   
Many other general cellular mechanisms have been related to vascular calcification, such as 
microRNA control of gene expression (57), endoplasmic reticulum stress (58), and activation of the 
inflammasome (59) etc. In contrast to Virchows’ early views, this apparently simple process of ectopic 
calcification has turned out to be much more complicated and complex than originally expected. 
Elucidation of the main regulatory mechanisms and differentiating them from secondary phenomena is 
one of the urgent pending questions that must be addressed. Specifically related to the involvement of 
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VSMC in VC, we must identify which cell types are involved in the osteochondrogenic trans-
differentiation and under what conditions; why do some cells respond apoptotically to endocytosis of 
nanocrystals, while other cells simply modify gene expression? And what are the specific conditions 
that determine apoptosis, necrosis, and other types of cell death as well as autophagy in the vessel 
wall?    
The success of on-going and future studies will enhance our understanding of these specific questions 
and add to our knowledge of VC pathogenesis. Figure 2 shows potential molecular pathogenic 
pathways associated with MMS. The triggering event responsible for precipitation of hydroxyapatite 
from the metastable supersaturated solution of calcium and phosphate within the environment of the 
media, i.e. VSMC and matrix, may result from both, presence of toxins, genetic predisposition and/or 
acquired deficiency in calcification inhibitors. 
 
Molecular Genetics  
There are several genetically defined vascular diseases associated with primary vascular media 
calcification and understanding the mechanisms regulating these diseases may shed light on the genes 
and mechanism involved in MMS. One monogenetic autosomal recessive disease that seems most 
closely to resemble the classical description of MMS is Arterial Calcification due to Deficiency of 
CD73 (ACDC), a rare vascular disease with medial calcifications (60, 61). In retrospect, it appears that 
ACDC patients were described as having atypical MMS, however, genetic confirmation on these 
patients cannot be pursued (62-64). ACDC patients develop massive vascular calcification in the 
medial layer of muscular type arteries primarily located in the lower-extremities (61). These patients 
have no indication of classic atherosclerosis, impaired kidney function or diabetes. ACDC patients 
have diminished lower limb perfusion with progressive, intermittent claudication. The ankle-brachial 
index (ABI) in ACDC patients is extremely low - below 0.3 - which clearly distinguishes it from 
MMS, where a typical ABI ranges between 1.1 and 2.0. Histological evaluations of affected vessels 
from ACDC patients demonstrate destruction of the medial wall with circumferential calcifications 
localized alongside broken elastic fibers within vessel wall. Medial disease progression leads to lumen 
occlusion due to medial dysplasia. ACDC is caused by loss-of-function mutations in the gene 
encoding for CD73 protein. This cell membrane bound extracellular enzyme generates adenosine and 
inorganic phosphate (Pi) from AMP, and is the primary enzyme to generate extracellular adenosine 
from purine precursors. The role of adenosine in vascular calcification appears intriguing and the 
discovery of ACDC opens up a new field of research as to the role of adenosine signaling on this 
disease phenotype. Experimental data suggest that adenosine signaling regulates tissue non-specific 
alkaline phosphatase (TNAP or ALPL), which is known as a known regulator of bone formation and 
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modulator of ectopic calcifications. Recently, the role of nucleosides and nucleotides in calcification 
prevention has been addressed and compared to PPi (65). 
 
Generalized Arterial Calcification in Infants (GACI, also referred to as Idiopathic Infantile Arterial 
Calcification) is another rare vascular disease with progressive and systemic vascular calcifications 
that develop in utero and during the early postnatal period (66). This fast-progressing vascular 
calcification disease has a high mortality rate early on in life. Histologically it is characterized by 
medial calcifications that lead to neointimal formation and vessel occlusion. This systemic vascular 
proliferative disease causes multi-organ failure due to non-atherosclerosis related myocardial 
infarction as early as 3 months of age. GACI is an autosomal recessive disease caused by mutations in 
the gene ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). This cell membrane bound 
extracellular enzymes generates AMP and pyrophosphate (PPi) from ATP and is therefore directly 
upstream of CD73, the causal gene for ACDC, in the extracellular purine metabolic pathway. PPi is a 
potent physiological inhibitor of TNAP and the lack of PPi and subsequent increase in TNAP activity 
is believed to be the main driver for this pathological malignant form of primary medial calcification.  
Familial idiopathic basal ganglia calcification (IBGC, also commonly known as Fahr’s disease) is 
third rare disease with a wide spectrum of neuropathological symptoms that have recently been 
attributed to the medial calcification of small blood vessel that supply the area of the basal ganglia 
(67). Genetic evaluations of a subset of IBGC families identified variants in the gene sodium-
dependent phosphate transporter 2 (SLC20A2 or PiT-2). PiT-2 is a Na
+
/Pi co-transporter that plays an 
important role in Pi homeostasis and may be functionally linked to ENPP1 and CD73 in extracellular 
purine metabolism. Involvement of PDGF signaling has been also recently reported (68).  
Overall these three distinct genetic vascular diseases, all with medial calcification as their common 
primary pathology, highlight the importance of extracellular purine metabolism and downstream 
adenosine signaling and phosphate homeostasis in the development of vascular media calcifications. 
The clinical presentation of primary MMS is clearly distinct from the devastating pathologies seen in 
patients suffering from ACDC, GACI and IBGC, however. It is therefore important to genetically 
evaluate this disease so that the full spectrum of the genetic causes of primary vascular media 
calcifications can be identified and understood. This will not only aid in the accurate diagnosis of 
patients with vascular calcification disorders, but will further the development of treatment strategies 






Functional Implications  
Arterial compliance (C) and distensibility (C/A) are given by the slope of the non-linear relation 
between the transmural pressure (p) and the luminal cross-sectional area (A), an expression of the 
elastodynamic coupling between the blood flow dynamics and vessel wall mechanics. The speed of 
the pressure wave, which is inversely proportional to the square root of the wall distensibility, can be 
also computed using the Moens-Korteweg equation (69). As calcium apatite deposits lowers the 
arterial distensibility, the pressure wave velocity (PWV) rises and causes premature wave reflection, 
thus impairing the left ventricular function (69). Altered left ventricular (LV) loading conditions result 
in LV hypertrophy and predispose to LV failure due to diastolic dysfunction while systolic function 
may remain preserved (70). Pathophysiological consequences of an increased pulsatility are less well 
understood. In a recent review arterial wall stiffening has been a strong independent predictor of future 
cardiovascular events and all-cause mortality (71).  
 
Based on the available evidence patients with MMS are likely to suffer from more profound vascular 
dysfunction of in addition to the frequently reported arterial wall stiffening and associated alterations 
of the LV loading. However, the precise nature of this vascular dysfunction remains unclear. We 
suggest three additional pathogenic principles potentially responsible for negative prognostic 
significance of MMS. First, the ring-like calcifications present in advanced MMS are likely to 
interfere with positive arterial remodeling in presence of atherosclerosis as described by Glagov et al. 
(72). In these cases would MMS clearly accelerate the co-incident atherosclerosis and worsen the 
organ perfusion. Second, stage 4 MMS with secondary invasion of the intima increases the risk of 
thromboembolic events. Third, MMS arteriolar lesions may be associated with alterations in 
mechanotransduction resulting in disturbances of autoregulation governing peripheral tissue perfusion. 
Here, sustained increase in systolic and pulse pressures in patients with MMS shall predictably cause 
arteriolar constriction, reduction of luminal cross-sectional area, augmented flow resistance and rise in 
blood pressure. Rise in blood pressure exceeding the upper limits of autoregulation, i.e. maximum 
vasoconstriction, would then increase, and while blood pressure falling below the lower limit of 
autoregulation, such as seen in patients with developing heart failure, would decrease peripheral tissue 
perfusion reflected by reciprocal changes in blood flow velocity in conduit vessels. To determine the 
true clinical relevance of MMS in addition to the measurements of PWV (73) also concurrent 
measurements of microcirculatory and endothelial functions employing for example the digital pulse 
volume measurement technology (74, 75) in clinical settings are needed. Furthermore, serial 
measurements of arterial dimensions in patients with MMS associated with POAD and/or diabetic 
macrovasculopathy are critical to determine the effects of MMS on compensatory positive arterial 




Diagnostic evaluations  
MMS is suggested by measuring the ankle-brachial index; MMS is diagnosed with an ABI ≥1.1. ABI 
readings of 1.1-1.3, 1.3-1.5 and >1.5 has been proposed to denote an early, intermediate and late 
MMS, respectively (76). In patients with suggested MMS (ABI ≥1.1) the toe-brachial index (TBI) has 
been proposed to improve the specificity of segmental blood pressure measurements (77). However, 
questions have been raised about the validity of this approach and the role of TBI in diagnostics of 
MMS remains uncertain (78). Nevertheless, despite limitations ABI remains the most important 
screening tool to suggest the presence of both, POAD and MMS (79).  
 
In clinical settings MMS is frequently identified accidentally from x-ray studies. In native x-ray 
images e.g. of lower extremities MMS lesions are visualized as symmetric narrowly–spaced, finely 
granular radiopaque rings often spanning the full diameter and the entire length of the artery. 
Similarity with railroad tracks was noted by Mönckeberg citing two other sources (13) and is also 
referred to in a more recent literature (80). With progressing disease the granulations become coarser 
and less regular.  
Figure 3a & 3b shows typical radiographic appearance of MMS lesions on native and angiographic x-
ray images. Figure 3c & 3d shows the progression of MMS after a 16 years follow-up in the same 
patient.  
 
Vascular ultrasound imaging allows clear differentiation of MMS and the atherosclerosis related 
lesions. In B-mode ultrasound images in patients with MMS distinct echogenic granular pattern 
located in the abluminal layers of the arterial walls and intact endothelial interfaces are seen. 
Depending on the stage of the disease MMS lesions can be small dots or larger confluent zones of 
echogenicity eventually spanning the entire vessel circumference on cross-sectional images (Figure 
4a). Visualization of MMS lesions on ultrasound can be optimized by focusing on the image layer 
containing the lesions (media) and employing Gaussian filtering at 6MHz (81). Employing the color 
flow duplex ultrasound both MMS calcifications and associated flow patterns can be visualized 
(Figure 4b). In patients with MMS undergoing endovascular interventions MMS- related lesions may 
be easily visualized employing intravascular ultrasound (IVUS) or optical coherence tomography 
(OCT). . On IVUS MMS lesions are seen as highly echogenic zones located within the media. Due to 
the presence of fibrotic tissue typically no acoustic ―shadowing‖ is seen (Figure 5a). In contrast, in 
calcifications of the intima as seen in atherosclerosis acoustic ―shadowing‖ is frequent. Compared to 
IVUS OCT provides higher resolution und substantially better visualization of the innermost layers of 
arterial walls. MMS lesions are distinctly visualized within the tunica media (Figure 5b).  
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While imaging studies employing conventional x-ray or ultrasound allow unequivocal definition of 
MMS, laboratory chemistries are non-specific; they are employed to assess the presence of associated 
diseases such as diabetes, chronic renal and endocrine disorders, and to assess the metabolic risk of 




In absence of causal therapy directed at prevention or treatment of MMS- associated lesions at present 
the therapeutic measures are directed at the co-existent diseases such as diabetes type II, chronic renal 
disease and atherosclerosis. Metabolic and hormonal control of diseases associated with altered 
handling of body calcium and phosphates appears critical to control the disease process.   
 
Perspectives  
To fully understand the pathophysiology, clinical significance and therapy for MMS patients, we 
propose the following steps: 
 
First: standard nomenclature of VC is needed. Cases of VC with unequivocally documented 
calcifications of the media should be separated from intimal forms. In this group, patients with 
identifiable risk factors (e.g. diabetes, chronic renal disease) and those without any such known risk 
factors (e.g. primary MMS) should be distinguished. Protocols to evaluate human vascular tissues (e.g. 
atherectomy specimen) from both groups of patients implementing genetic and molecular technology 
should be developed.  
 
Second: morphological studies should be conducted  to determine the systemic incidence of MMS in 
different vascular beds, including microcirculation.   
 
Third: determine the clinical impact of MMS on cardiovascular health. Comprehensive evaluations 
and serial measurements of arterial dimensions, arterial wall stiffness and peripheral tissue perfusion 
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Figure 1a: MMS stage 1. Deposits consisting of fine granulations, which increase in size and become 
confluent with time are shown (H & E-stain, light microscope, x 200). 
Figure 1b: Ultrastructure of calcified deposits. Ultrastructurally, calcified deposits are largely 
associated with damaged and fractured elastic fibers embedded within the extracellular matrix 
(Electron microscopy, x 50000, figure with permission of Perfusion, Janzen et al. 2006). 
Figure 1c: MMS stage 1.  Granular calcifications alongside the internal elastic membrane giving rise 
to a blue band are demonstrated. (Differential eosin fluorescence pattern, laser scanning microscope, x 
400). 
Figure 1d: MMS stage 2. Medial calcifications may distort the junctions of the innermost and 
outermost layers spanning up to three quadrants of the cross-section and consisting of calcified plates. 
(H 6 E-stain, light microscope, x 40). 
Figure 1e: MMS stage 3.  Calcified plates involving the entire arterial circumference are 
demonstrated. (H 6 E-stain, light microscope, x 40). 
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Figure 2 Pathogenesis of MMS. Shown are molecular pathways potentially associated with initiation 
and propagation of MMS. 
Figure 3a, b.  X-ray image of a femoral bifurcation with typical appearance of MMS of the superficial 
femoral (SFA) and deep femoral arteries on native x-ray (left) and selective needle angiogram of the 
same bifurcation (right). Typical appearance of Mönckeberg’s media sclerosis showing ―railroad 
trucks‖ pattern on native x-ray images can be appreciated.  
Figure 3c, d. Progression of MMS over a period of 16 years. Shown are native x-ray images of the left 
upper thigh of a 46 years old male (left) and of the same male on 16 years follow-up. Coarser and less 
regular pattern of MMS calcifications can be appreciated.  
Figure 4a. Shown are ultrasound images of patients with MMS without (upper panels and left lower 
panel) and with (right lower panel) atherosclerosis. Granular pattern of calcification can be clearly 
seen on longitudinal and cross-sectional (insert) views (left upper panel). Formation of solid calcific 
plates (upper right panel) and irregular continuous calcifications (left lower panel) are also 
demonstrated. Concurrent presence of MMS lesions (abluminal echogenecities) and atherosclerotic 
lesions (intraluminal echogenecities) is also visualized (right lower panel) (courtesy C. Garn).  
Figure 4b. Shown are ultrasound images of a patient with MMS employing B-mode and color Doppler 
mode techniques. Medial calcifications (both images) and unperturbed intraluminal blood flow are 
clearly seen (right).  
Figure 5a. Intravascular cross-sectional ultrasound image of the proximal superficial femoral artery in 
a patient with MMS is shown. Dense tunica media calcification (arrows), absence of acoustic 
shadowing and freedom from intimal atherosclerotic disease should be noted (Eagle Eye catheter, 
Volcano, 20MHz, lateral resolution 200-250µ, axial resolution 80-100µ).  
Figure 5b. Optical coherence tomography cross-sectional image of the proximal superficial femoral 
artery with circumferential media-calcinosis (white arrows) interrupted by a bigger side-branch located 
at 3 o’clock. The yellow arrows mark intraluminal prolapsing fibrotic plaque. § = OCT catheter, * 




A. Historical perspective  
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Diseases of arterial walls associated with focal calcifications have been noted by pathologists for 
centuries. However, the first systematic review can likely be attributed to Johann Friedrich Lobstein. 
In the second volume of his textbook of general and special pathology he devoted 56 pages to the 
diseases involving arterial walls and termed arterial diseases associated with thickening and hardening 
of arteries arteriosclerosis (Lobstein JCCFM. Traite d’Anatomie pathologique. 2 volumes. Paris:F-G 
Levault, 1829-1833; Lobstein JCCFM. Lehrbuch der pathologischen Anatomie. Band 1 und 2. 
Stuttgart:F. Brodhag, 1834-1835). Roughly half a century later and for similar group of arterial 
diseases Felix Marchand has coined the term atherosclerosis (Marchand F. Ueber Arteriosklerose. 
Verhandlungen des Congresses für Innere Medicin. Einundzwanzigster (21.) Congress. Gehalten zu 
Leipzig, vom 18. - 21. April 1904. Mit 11 Tafeln und 15 Textabbildungen. (Beiträge von/über: den 
Wert der Blutdruckmessung für die Behandlung der Ateriosklerose, Anatomische Befunde am 
Circulations-Apparate, speziell den Arterien bei Typhus abdominalis, Zur Bestimmung der 
Leistungsfähigkeit des gesunden und kranken Herzens durch Muskelarbeit, u.a.). Wiesbaden: JF 
Bergmann, 1904;21:23-59).  
In his treaties, Virchow noted the difference between calcifications of the arterial intima and media, 
and stated that calcifications of the intima appeared of inflammatory origin while those of media did 
not and pointed out similarities between calcifications of arteries and ossifications of the bone in these 
calcification (Virchow R. Cellularpathologie; in ihrer Begründung auf physiologische und 
pathologische Gewebelehre. 4 Auflage, Berlin: A. Hirschwald, 1871; p. 452-453). In 1903 
Mönckeberg conducted at the behest of his teacher, Eugen Fränkel study of medial vascular 
calcifications and confirmed the distinction between the calcific diseases of the media and intima 
(Mönckeberg JG. Über die reine Mediaverkalkung der Extremitätenarterien und ihr Verhalten zur 
Arteriosklerose. Virchows Archiv für pathologische Anatomie und Physiologie, und für klinische 
Medicin, Berlin, 1903, 171: 141-167). Based on macroscopic examinations of arteries of the lower and 
upper extremities from 130 cases with additional light microscopic evaluation in 86 of these cases 
Mönckeberg found calcification of the tunica media with no evidence of atherosclerosis in 55 cases 
(age 35-85 years; 39 males, 16 females). On hematoxylin-eosin staining, H&E, Mönckeberg found 
granular calcium deposits in the media; in more advanced stages calcific buckles, plates and rings 
were found corresponding to the macroscopic appearance and roentgenographic images of the 
Gänsetrachea (windpipe of the goose). Depending of the amount and degree of calcifications of the 
tunica media Mönckeberg observed secondary stretching, bulging and perforations of the internal and 
external elastic laminae along with destruction of smooth muscle layer. In most advanced cases the 
arteries have been transformed into rigid pipes. Interestingly, in four cases, all males, with isolated 
calcifications of the media the affected individual were younger than 50 years old with two of the men 
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being less than 40 years old. Overall, calcifications of the tunica media were most frequent in femoral 
arteries (42 cases). 
Subsequently, vascular calcifications primarily located in the arterial tunica media were termed 
Mönckeberg’ Media Sclerosis (MMS), Mönckeberg’s later attempted to defend and to justify the 
nosologic distinctness of the intima- and media- related vascular calcification (Mönckeberg JG. 
Mediaverkalkung und Atherosklerose. Virch Arch Pathol Anat Physiol klin Med 1914;216:408-416) 
have remained a matter of debate until present (Micheletti RG, Fishbein GA, Currier JS, Fishbein MC. 
Mönckeberg sclerosis revisited; a clarification of the histologic definition of Mönckeberg’s sclerosis. 
Arch Pathol Lab Med 2008;132:43-47). In consequence the nomenclature of calcific aterial disorders 
remains unsettled. 
 
B. Diseases reported to be associated with Mönckeberg’s media sclerosis 
Diseases other than diabetes mellitus and chronic renal disease associated with Media Sclerosis 
Mönckeberg have been summarized in the table. 
 
Diabetes mellitus type II Edmonds ME, Morrison N, Laws JW, Watkins PJ. Medial arterial 
calcification and diabetic neuropathy. Br Med J Clin Res Ed 
1982;284:928-30. 
Chronic renal disease Chen NX, Moe SM. Uremic vascular calcification. J Invest Med 
2006;54:380-384. 
Osteoporosis Rubin MR, Silverberg SJ. Vascular Calcification and 
Osteoporosis—The Nature of the Nexus. J Clin Endocrinol Metab 
2004, 89:4243–4245. 
Hyperparathyreoidism  Terai K, Nara H, Takahura K, Mizukami K, Sanagi M, Fukushima 
S, Fujimori A, Itoh H, Okada M. Vascular calcification and 
secondary hyperparathyroidism of severe chronic kidney disease 
and its relation to serum phosphate and calcium levels. British J 
Pharmacol 2009;156:1267–1278. 
Vitamin D hyper- and 
hypovitaminoses 
 Drüeke TB, Massy ZA. Role of vitamin D in vascular calcification: 
bad guy or good guy? Nephrol Dial Transplant 2012;27:1704-1707; 
Malick NP, Berlyne GM. Arterial calcification after vitamin-D 




Autonomic neuropathy Goebel FD, Fuessl HS. Monckeberg’s sclerosis after sympathetic 
denervation in diabetic and non-diabetic patients. Diabetologia 
1983;24:347-350 
Ehlers-Danlos syndrome  McKusick VA. Heritable disorders of connective tissue. St. Louis: 
CV Mosby, 1972. 
Pseudoxanthoma elasticum  Lebwohl M, Halperin M, Phelps RG. Occult pseudoxanthoma 
elasticum in patients with premature cardiovascular disease. N Engl 
J Med 1993;329:1237-1239. 
Systemic sclerosis Son CN, Jung KH, Song SY, Jun JB. Monckeberg’s sclerosis in a 
patient with systemic sclerosis. Rheumatol Int 2009;30:105-107. 
β-Thalassemia Aessopos A, Samarkos M, Voskaridou E, Papaioannou D. Kavoukis 
E, Vasopoulos G, Stamatelos G. Loukopoulos D. Arterial 
calcifications in beta-thalassemia. Angiology 1998;49:137-143. 
Kawasaki-disease  Ino T, Shimazaki S, Akimoto K, Park I, Nishimoto K, Yabuta K, 
Tanaka A. Coronary artery calcifications in Kawasaki disease. 
Pediatr Radiol 1990;20:520-523. 
Singelton-Merten-Syndrom  Singleton EB, Merten DF. An unusual syndrome of wiedened 
medullary cavities oft he metacarpals and phalanges, aortic 
calcification and abnormal dentition. Pediatr Radiol 1973;1:2-7 
 Generalized arterical 
calcification of infants 
 Maayan C, Pele O, Eyal F, Mogle P, Rosenman E. Ziv JB. 
Idiopathic infantile arterial calcification: a case report and review of 
the literature. Eur J Pediatr 1984;142:211-215. 
Arterial Calcification due to 
Deficiency of CD73 
St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, 
Carlson-Donohoe H, Lederman RJ, Chen MY, Yang D, 
Siegenthaler MP, Arduino C, Mancini C, Freudenthal B, Stanescu 
HC, Zdebik AA, Chaganti RK, Nussbaum RL, Kleta R, Gahl WA, 
Boehm M. Nt5e mutations and arterial calcifications. N Engl J Med 
2011;364:432-442 
Idiopathic basal ganglia 
calcification 
Wang C, Li Y, Shi L, Ren J, Patti M, Wang T, de Oliveira JR, 
Sobrido MJ, Quintans B, Baquero M, Cui X, Zhang XY, Wang L, 
Xu H, Wang J, Yao J, Dai X, Liu J, Zhang L, Ma H, Gao Y, Ma X, 
Feng S, Liu M, Wang QK, Forster IC, Zhang X, Liu JY. Mutations 
in slc20a2 link familial idiopathic basal ganglia calcification with 
phosphate homeostasis. Nat Genet. 2012;44:254-256 
25 
 
Rheumatoid arthritis treated 
with cortisone 
 Amos RS, Wright V. Mönckeberg’s arteriosclerosis and metabolic 
bone disease. Lancet 1980;ii:248-249. 
Elderly and aged persons Johnson RC, Leopold JA, Loscalzo J. Pathobiological mechanisms 
and clinical implications. Circ Res 2006;99:1044-1059 
 
Tables 
Table 1. Conditions associated with Mönckeberg’s media sclerosis.  
Condition Laboratory examination Comments 
Atherosclerosis Lipoprotein and Glucose 
metabolism analysis 
Screening (Duplex carotis, 
ABI), polyvascular disease? 
Diabetes Glucose (fasting, profile) 
HbA1c 
Endorgan involvement? 
Renal disease Creatinine, Glomerular 
filtration rate, Urea, Phosphate, 
Calcium 
Osteoporosis? 
Parathormon related disorders Calcitriol (1,25[OH]2D3, intact 
parathormon (iPTH) 
Thyroid disease, hypophyseal 
disorders 
β-thalasemia Hb, Ferritin, Hb-electrophoresis  
Vitamin D3 related disorders Calcitriol (1,25[OH]2D3  




corticosteroids or cortison 
related disorders 
Cortisone Rheumatic diseases? 
Pseudoxanthoma elasticum Skin biopsy, genetic testing for 
ABCC6, recessive 
Adolescence, habitus, Clinical 
overlap with GACI 
Arterial Calcification due to 
Deficiency of CD73 
Genetic testing for CD73 
variants, recessive 
Early adulthood, decreased 
ABI, decreased limb perfusion 
Idiopathic basal ganglia 
calcification 
Genetic testing for SLC20A2, 
PDGF-B 
Cerebral vascular calcifications, 
neurological defects 
Singleton-Mertens syndrome  Childhood, adolescence, 
habitus, teeth dyplasias 
Idiopathic arterial calcification Genetical testing Newborn, early childhood 
Generalized arterical Genetical testing for ENPP1 Newborn, early childhood, 
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calcification of infants variants, recessive clinical overlap with PXE 
*TNF – tumor necrosis factor, IL- interleukin 
 
 
 
